All In Biotech

Drug Trial Radar · NCT00637377

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Dec 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,240

Actual

Start

Apr 2008

Primary completion

Sep 2010

Study completion Aug 2011

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Mar 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.

Conditions

  • Macular Degeneration

Interventions

  • RanibizumabDrug

    Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Biological

    Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Biological

    Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Biological

    Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)Time frame: At week 52

Locations

189 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Córdoba, Córdoba Province, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    Parramatta, Australia

  • Site not named

    Chatswood, New South Wales, Australia

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Westmead, New South Wales, Australia

  • Site not named

    East Melbourne, Victoria, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Nedlands, Western Australia, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Liège, Belgium

  • Site not named

    Minas Gerais, Brazil

  • Site not named

    Ribeirão Preto, São Paulo, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Medellín, Antioquia, Colombia

  • Site not named

    Bogotá, Bogota D.C., Colombia

  • Site not named

    Cali, Cauca Department, Colombia

  • Site not named

    Brno, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Besançon, France

  • Site not named

    Bordeaux, France

  • Site not named

    Dijon, France

  • Site not named

    Lyon, France

  • Site not named

    Lyon, France

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

  • Site not named

    Nantes, Cedex 1, France

  • Site not named

    Paris, Cedex 12, France

  • Site not named

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.